海外の治験の状況「1」での検索結果
1037件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Not recruiting
- AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- Small Cell Lung Cancer
- Australia, Austria, Belgium, Bulgaria, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom, United States
- 2007-10-18
Not Recruiting
- First line standard therapy of glioblastoma multiforme with or without add-on treatment with Trivax, an anti-tumour immune therapy based on tumour-lysate charged dendritic cells - GBM-Vax
- Patients older than 3 years of age with newly diagnosed Glioblastoma Multiforme (GBM) undergoing brain surgery for removal of at least 70% of tumour mass and receiving subsequently standard radiation therapy and standard chemotherapy with temozolomide. MedDRA version: 14.1 Level: PT Classification code 10018337 Term: Glioblastoma multiforme System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Austria
- 2009-12-22
Not recruiting
- BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
- Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma;Carcinoma, Non-Small-Cell Lung;Adenocarcinoma
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Korea, Republic of, Malaysia, Mexico, Peru, Philippines, Romania, Russian Federation, Taiwan, Thailand, Ukraine, United Kingdom, United States
- 2009-07-29
Not recruiting
- Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Neoplasms, Ovarian;Neoplasms, Ovarian;Neoplasms, Ovarian;Neoplasms, Ovarian
- Australia, Austria, Belgium, China, Denmark, France, Germany, Hong Kong, Ireland, Italy, Japan, Korea, Republic of, Norway, Spain, Sweden, Taiwan, United States
- 2009-03-19
Not Recruiting
- A prospective, multicenter, randomized, rater- and subject-blind, parallel group trial to investigate the non-inferiority of NT 201, free of complexing proteins, in comparison with Clostridium botulinum toxin type A in the treatment of glabellar frown line - NT-H2H
- Treatment of glabellar frown lines br>MedDRA version: 10.1 Level: LLT Classification code 10052609 Term:
- Austria, Germany
- 2008-08-27
Not Recruiting
- A 24-week, multicenter, international, randomized (1:1), parallel-group, open-label, comparative study of insulin glargine versus liraglutide in insulin-naïve patients with Type 2 diabetes treated with oral agents and not adequately controlled, followed by a 24-week extension period with insulin glargine for patients not adequately controlled with liraglutide - EAGLE (Efficacy Assessment of insulin Glargine versus LiraglutidE after oral agents failure)
- Type 2 diabetes not adequately controlled MedDRA version: 14.1 Level: LLT Classification code 10063624 Term: Type II diabetes mellitus inadequate control System Organ Class: 10027433 - Metabolism and nutrition disorders
- Austria, Czech Republic, Finland, France, Greece, Ireland, Netherlands, Spain, Sweden
- 2010-04-09
Not Recruiting
- A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2 - Everest 2
- K-Ras wild type metastatic colorectal cancer MedDRA version: 12.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastatic
- Austria, Belgium, Hungary, Spain
- 2010-09-10
Not Recruiting
- PENTA18: Pharmacokinetics, safety and efficacy of lopinavir/ritonavir tablets in combination antiretroviral therapy in human immunodeficiency virus-1 (HIV-1) infected children
- Infectious disease - Paediatric HIV Infections and Infestations Human immunodeficiency virus
- Austria, Belgium, Brazil, Denmark, Germany, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Thailand, United Kingdom
- 2009-07-10
Not Recruiting
- Randomised comparative study of folfox6m plus SIR-Spheres microspheres versus folfox6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma
- Non-resectable liver metastasis from primary colorectal carcinoma MedDRA version: 17.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04];Non-resectable liver metastasis from primary colorectal carcinoma MedDRA version: 17.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04];Non-resectable liver metastasis from primary colorectal carcinoma MedDRA version: 17.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Belgium, France, Germany, Israel, Italy, New Zealand, Spain, United States
- 2008-10-01
Not Recruiting
- A Phase III, open-label, multicenter trial of avelumab (MSB0010718C) versus platinum-based doublet as a first-line treatment of recurrent or Stage IV PD-L1+ non–small-cell lung cancer
- -C34 Malignant neoplasm of bronchus and lung Malignant neoplasm of bronchus and lung;Malignant neoplasm of bronchus and lung
- Australia, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Japan, Korea South, Lithuania, Malasya, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Taiwan, Thailand, Turkey, United Kindgdom, United States
- 2016-05-16